Sign In
Buy OMER
$10.16
-0.1000 (-0.97%)
At Close: Jun 03, 2026
Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting
04:43pm, Friday, 17'th Oct 2025
Omeros Corporation maintaining a Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for MASP-3 inhibitor zaltenibart. OMER's zaltenibart targets Paroxysmal Nocturnal Hemoglo
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
12:10pm, Thursday, 16'th Oct 2025
Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.
Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case
10:08am, Thursday, 16'th Oct 2025
Omeros Corporation's stock surged over 150% after licensing zaltenibart to Novo Nordisk for $340M upfront, plus milestones and royalties. The deal provides OMER with critical funding, alleviating bank
Can OMER stock retain Novo Nordisk driven gains over the long-term?
10:00am, Thursday, 16'th Oct 2025
Omeros Corporation (NASDAQ: OMER) opened over 150% up this morning after announcing a new licensing agreement worth up to $2.1 billion with the Bagsværd-headquartered Novo Nordisk. According to OMER'
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?
03:39am, Thursday, 16'th Oct 2025
Shares of Omeros (OMER 153.90%) finished Oct. 14's trading session at $4.10 per share. When the market opened on Oct. 15, the stock was up by 181% at $11.52 per share.
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal
02:58pm, Wednesday, 15'th Oct 2025
Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on We
Can OMER stock retain Novo Nordisk driven gains over the long-term?
11:54am, Wednesday, 15'th Oct 2025
Omeros Corporation (NASDAQ: OMER) opened over 150% up this morning after announcing a new licensing agreement worth up to $2.1 billion with the Bagsværd-headquartered Novo Nordisk. According to OMER'
Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug
09:17am, Wednesday, 15'th Oct 2025
Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart.
Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push
08:32am, Wednesday, 15'th Oct 2025
Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and kidney disord
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
08:30am, Wednesday, 15'th Oct 2025
Bagsværd, Denmark and Seattle, US, 15 October 2025 – Novo Nordisk and Omeros Corporation (Nasdaq: OMER) today announced that they have entered into a definitive asset purchase and license agreement
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and
Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript
04:41pm, Tuesday, 19'th Aug 2025
Omeros Corporation (NASDAQ:OMER ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Catherine A. Melfi - Chief Regulatory Officer & VP of Regulatory Affairs and Quality
Omeros Corporation Reports Second Quarter 2025 Financial Results
04:02pm, Thursday, 14'th Aug 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include: N
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
04:02pm, Monday, 11'th Aug 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2025, on Thursday, August 14, 2025, after
